This lecture was presented at the Royal Australian and New Zealand College of Ophthalmologists Annual Meeting, Adelaide, SA, October 2001.
Current trends in the treatment of ocular melanoma by radiotherapy
Article first published online: 12 FEB 2003
Clinical & Experimental Ophthalmology
Volume 31, Issue 1, pages 8–13, February 2003
How to Cite
Hungerford, J. L. (2003), Current trends in the treatment of ocular melanoma by radiotherapy. Clinical & Experimental Ophthalmology, 31: 8–13. doi: 10.1046/j.1442-9071.2003.00611.x
- Issue published online: 12 FEB 2003
- Article first published online: 12 FEB 2003
- plaque therapy;
- posterior uveal melanoma;
- proton therapy;
The Collaborative Ocular Melanoma Study (COMS) has recently confirmed once and for all that it is safe to attempt to preserve an eye with a posterior uveal melanoma by demonstrating no survival advantage of enucleation over plaque radiotherapy. While COMS has been under way, we have set out in London to define the selection criteria for conservative therapy versus enucleation for the various categories of melanoma in terms of size, location within the eye, and presence or absence of retinal detachment. The evolution of this approach has culminated in an overall ocular survival rate of 94% in 597 patients following radiation therapy combined with a mean loss of visual acuity of only 2.4 Snellen lines in the eyes preserved.